Skip to content

Study · In vitro (cells) · japanese tree frog receptor in cho-k1 cells · 2003

1 result

Molecular cloning of an anuran V(2) type [Arg(8)] vasotocin receptor and mesotocin receptor: functional characterization and tissue expression in the Japanese tree frog (Hyla japonica).

Kohno S, Kamishima Y, Iguchi T

General and comparative endocrinology1 Jul 2003Cited by 44 (Europe PMC)

PMID12849972 (opens in a new tab)DOI10.1016/s0016-6480(03)00140-0 (opens in a new tab)PepBankPUB-12849972
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In CHO-K1 cells with the tree frog vasotocin receptor, oxytocin raised cAMP accumulation less than vasotocin and vasopressin, equal to mesotocin and more than isotocin.

    In plain wordsIn cells carrying a frog receptor, oxytocin raised cAMP, weaker than vasotocin and stronger than isotocin.

    Peptide
    Oxytocin
    Outcome
    IncreasecAMP accumulation via tree frog vasotocin receptor
    Study

    Japanese tree frog receptor in CHO-K1 cellsn: not reported in source

    CHO-K1 cells transfected with tree frog VTR
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    VT = hydrin 1 > or = vasopressin > or = hydrin 2 > MT = oxytocin > isotocin.
    1 context sentence
    Summary · context
    Using CHO-K1 cells transfected with tree frog VTR, we observed elevated concentrations of intracellular cAMP following exposure of the cells to VT or other neurohypophysial hormones, whereas the cells transfected with MTR did not exhibit altered cAMP concentrations.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:53 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.